AstraZeneca (Italy)

AstraZeneca (Italy)

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for AstraZeneca (Italy), Italy, covering academic research published from 2000 to 2023. Read More.


Open Access Percentage

65%


Total
Publications

112


Total Open
Publications

73


Total
Citations

3.9K


Open Access
Percentage

65%


Total
Publications

112


Total Open
Publications

73


Total
Citations

3.9K

Wikipedia

Website

download

Breakdown

30% 31% 4% 35%

Publisher Open

30%

Both

31%

Other Platform Open

4%

Closed

35%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

02468101214161820Total Publications
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023

Open

Closed

Publisher Open

31%OA Journal

OA Journal 31%

21

Hybrid 39%

27

No Guarantees 30%

21

Other Platform Open

Domain 62%

24

Institution 33%

13

Other Internet 31%

12

Preprint 8%

3

Public 5%

2

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
24
INFN Catania - INFM-OAR
Other Internet
5
Europe PMC
Domain
5
University of Groningen / Centre for Information Technology - University of Groningen research database
Institution
4
University of Turin - Institutional Research Information System University of Turin
Institution
3
Tor Vergata University - Cineca Institutional Research Information System
Other Internet
3
Universita Degli Studi Di Milano - Archivio Istituzionale della Ricerca
Institution
2
unisi.it OAI-PMH Repository
Institution
2
no - no
Institution
2
Le Centre pour la Communication Scientifique Directe - HAL - memSIC
Other Internet
2
1 / 3

Data updated 7 October 2024

Share

Share

Share